In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
Pineapple pact shows fruits of collaboration on Earth Day
In California, Dole Packaged Foods has partnered with circular design firm Rais Case and Ananas Anam, creator of pineapple-based textile Piñatex®, to tackle pineapple...
Project converting chicken feathers into cultivated chicken meat concludes first phase
In Italy, a research project looking to grow cells from chicken feathers into chicken meat has concluded its first phase by generating a batch...
Vote for sustainability: Bioplastic dummy ballots used to spread voter awareness
In India, IIT Guwahati has developed 3D-printed dummy ballots made of biobased polylactic acid.
Commissioned by the Systematic Voters' Education and Electoral Participation Cell, the...